AIMS: Erythropoiesis-stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse events. Hepcidin production, controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin. High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anaemia in CKD patients. To investigate alternative therapies to erythropoiesis-stimulating agents for CKD patients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKD patients. METHODS: Preclinical in vitro/vivo data and clinical data in healthy subjects and CKD patients were used to illustrate the translation of pharmacological properties of LY3113593 and LY2928057, highlighting the novelty of targeting these nodes within the hepcidin-ferroportin pathway. RESULTS: LY2928057 bound ferroportin and blocked interactions with hepcidin, allowing iron efflux, leading to increased serum iron and transferrin saturation levels and increased hepcidin in monkeys and humans. In CKD patients, LY2928057 led to slower haemoglobin decline and reduction in ferritin (compared to placebo). Serum iron increase was (mean [90% confidence interval]) 1.98 [1.46-2.68] and 1.36 [1.22-1.51] fold-relative to baseline following LY2928057 600 mg and LY311593 150 mg respectively in CKD patients. LY3113593 specifically blocked BMP6 binding to its receptor and produced increases in iron and transferrin saturation and decreases in hepcidin preclinically and clinically. In CKD patients, LY3113593 produced an increase in haemoglobin and reduction in ferritin (compared to placebo). CONCLUSION:LY3113593 and LY2928057 pharmacological effects (serum iron and ferritin) were translated from preclinical-to-clinical development. Such interventions may lead to new CKD anaemia treatments.
RCT Entities:
AIMS: Erythropoiesis-stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse events. Hepcidin production, controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin. High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anaemia in CKDpatients. To investigate alternative therapies to erythropoiesis-stimulating agents for CKDpatients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKDpatients. METHODS: Preclinical in vitro/vivo data and clinical data in healthy subjects and CKDpatients were used to illustrate the translation of pharmacological properties of LY3113593 and LY2928057, highlighting the novelty of targeting these nodes within the hepcidin-ferroportin pathway. RESULTS:LY2928057 bound ferroportin and blocked interactions with hepcidin, allowing iron efflux, leading to increased serum iron and transferrin saturation levels and increased hepcidin in monkeys and humans. In CKDpatients, LY2928057 led to slower haemoglobin decline and reduction in ferritin (compared to placebo). Serum iron increase was (mean [90% confidence interval]) 1.98 [1.46-2.68] and 1.36 [1.22-1.51] fold-relative to baseline following LY2928057 600 mg and LY311593 150 mg respectively in CKDpatients. LY3113593 specifically blocked BMP6 binding to its receptor and produced increases in iron and transferrin saturation and decreases in hepcidin preclinically and clinically. In CKDpatients, LY3113593 produced an increase in haemoglobin and reduction in ferritin (compared to placebo). CONCLUSION:LY3113593 and LY2928057 pharmacological effects (serum iron and ferritin) were translated from preclinical-to-clinical development. Such interventions may lead to new CKD anaemia treatments.
Authors: David M Frazer; Sarah J Wilkins; Deepak Darshan; Alison C Badrick; Gordon D McLaren; Gregory J Anderson Journal: Br J Haematol Date: 2012-03-26 Impact factor: 6.998
Authors: Sharraya Aschemeyer; Bo Qiao; Deborah Stefanova; Erika V Valore; Albert C Sek; T Alex Ruwe; Kyle R Vieth; Grace Jung; Carla Casu; Stefano Rivella; Mika Jormakka; Bryan Mackenzie; Tomas Ganz; Elizabeta Nemeth Journal: Blood Date: 2017-12-13 Impact factor: 22.113
Authors: Igor Theurl; Andrea Schroll; Manfred Nairz; Markus Seifert; Milan Theurl; Thomas Sonnweber; Hasan Kulaksiz; Guenter Weiss Journal: Haematologica Date: 2011-08-22 Impact factor: 9.941
Authors: Elizabeta Nemeth; Marie S Tuttle; Julie Powelson; Michael B Vaughn; Adriana Donovan; Diane McVey Ward; Tomas Ganz; Jerry Kaplan Journal: Science Date: 2004-10-28 Impact factor: 47.728
Authors: A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin Journal: N Engl J Med Date: 1998-08-27 Impact factor: 91.245
Authors: Matthew Sheetz; Philip Barrington; Sophie Callies; Paul H Berg; Juliet McColm; Thomas Marbury; Brian Decker; Gregory L Dyas; Stephanie M E Truhlar; Robert Benschop; Donmienne Leung; Jolene Berg; Derrick R Witcher Journal: Br J Clin Pharmacol Date: 2019-03-04 Impact factor: 4.335
Authors: Verena Petzer; Piotr Tymoszuk; Malte Asshoff; Joana Carvalho; Jonathan Papworth; Cecilia Deantonio; Luke Bayliss; Matthew Stephen Wake; Markus Seifert; Natascha Brigo; Lara Valente de Souza; Richard Hilbe; Philipp Grubwieser; Egon Demetz; Stefanie Dichtl; Chiara Volani; Sylvia Berger; Felix Böhm; Alexander Hoffmann; Christa Pfeifhofer-Obermair; Laura von Raffay; Sieghart Sopper; Stephanie Arndt; Anja Bosserhoff; Léon Kautz; Prunelle Perrier; Manfred Nairz; Dominik Wolf; Guenter Weiss; Volker Germaschewski; Igor Theurl Journal: Blood Date: 2020-08-27 Impact factor: 22.113